AHA: After Stenting in Afib, Xarelto-Based Anticoagulation Reduces Bleeding Low-dose rivaroxaban strategies also reduced rehospitalizations
NEW ORLEANS — After stenting patients with atrial fibrillation (Afib), a course of rivaroxaban (Xarelto) — in combination with either a P2Y12 inhibitor or dual antiplatelet therapy (DAPT) — was safer than a warfarin-DAPT combination, a late-breaking trial showed.